



Patent
HDAC-5003-U

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Xiao Yi Xiao et al.

Serial No.: 10/682,496

Filed: October 9, 2003

For: HISTONE DEACETYLASE
INHIBITORS

)
) Group Art Unit: 1626

)
) Examiner: Freistein, Andrew B.

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 CFR §§ 1.97 and 1.98, the items identified in this Information Disclosure Statement ("IDS") are brought to the attention of the Office. The items are listed on the attached form PTO-1449. As copies of U.S. patents and applications are no longer required by the Office, copies are not being submitted with this IDS. However, if the Examiner would like copies of the U.S. cited references, Applicant will provide the references upon request.

The items identified in this IDS may or may not be "material" pursuant to 37 CFR § 1.56. The submission thereof by Applicant is not to be construed as an admission that any such patent, publication or other information referred to therein is material or considered to be material (37 CFR § 1.97(h)), or even qualifies as "prior art" under 35 USC § 102 with respect to this invention unless specifically designated by Applicant as such.

02/02/2006 HDESTA1 00000008 502256 10682496


03 FC:1806 180.00 DA

CERTIFICATE OF MAILING (37 C.F.R. § 1.8)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage in an envelope addressed to the Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

January 30, 2006
Date of Deposit

Jennifer L. Sammartin
Name of Person Mailing Paper


Signature of Person Mailing Paper

INFORMATION DISCLOSURE STATEMENT FILING PROVISION:

☐ This IDS is believed to be timely in that it is being submitted under 37 CFR § 1.97(b), that is (1) within three months of the filing date of the application, which is not a continued prosecution application filed under § 1.53(d) or (2) within three months of entry of the national stage as set forth in 37 CFR § 1.491; or (3) before the mailing of a first Office action on the merits; or (4) before the mailing of a first Office action after filing a request for continued examination under § 1.114. Thus, no fee is required.

☐ However, if the undersigned is in error in this regard, Applicant respectfully requests that the Office consider this IDS as filed under 37 CFR § 1.97(c), if applicable, and charge the fee due under 37 CFR § 1.17(p) to the deposit account referenced below.

☐ However, if the undersigned is in error in this regard, Applicant respectfully requests that the Office consider this IDS as filed under 37 CFR § 1.97(c), if applicable, and a statement under 37 CFR § 1.97(e) is included below, thus no fee is required.

☒ This IDS is being submitted under 37 CFR § 1.97(c), that is after mailing of a first Office action on the merits, but before a Final Action under 37 CFR § 1.113 or a Notice of Allowance under 37 CFR § 1.311.

☒ The fee due under 37 CFR § 1.17(p) is submitted herewith.

☐ A statement under 37 CFR § 1.97(e) is included below, thus no fee is required. In the event that this IDS is not received before a Final Action or a Notice of Allowance, then Applicant respectfully requests that the Office consider the filing of these papers to be submitted under 37 CFR § 1.97(d) and charge the fee due under 37 CFR § 1.17(p) to the deposit account below.

☐ This IDS is being submitted under 37 CFR § 1.97(d), that is after a Final Action under 37 CFR § 1.113 or a Notice of Allowance under 37 CFR § 1.311, but before payment of the issue fee. A statement under 37 CFR § 1.97(e) is included below. The fee due under 37 CFR § 1.17(p) is submitted herewith.

STATEMENT UNDER 37 CFR § 1.97(e):

☐ Each item contained in this IDS was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS.

☐ No item contained in this IDS was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing

this statement after making reasonable inquiry, no item of information contained in this IDS was known to any individual designated in 37 CFR § 1.56(c) more than three months prior to the filing of this IDS.

PAYMENT AND/OR AUTHORIZATION TO CHARGE FEES:


- ☐ A check in the amount of _____ is enclosed for the above fee(s).
☒ Please charge to Deposit Account No. **50-2256** for the above fee(s).

Although Applicants do not believe any additional fees are required, the Commissioner is authorized to charge any additional fees required by the filing of these papers to Takeda's Deposit Account No. **50-2256**.

Respectfully submitted,

TAKEDA SAN DIEGO, INC.

Dated: January 30, 2006

By: 
David J. Weitz
Reg. No. 38,362

Customer No. **32793**
Takeda San Diego, Inc.
10410 Science Center
San Diego, CA 92121
Tel: (858) 622-8528
Fax: (858) 550-0992



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|--------------------------|---------------------|------------------------|-----------------|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Complete if Known | | | |
| | | Application Number | 10/682,496 | | |
| | | Filing Date | October 9, 2003 | | |
| | | First Named Inventor | Andrew B. Freistein | | |
| | | Group Art Unit | 1626 | | |
| | | Examiner Name | Not Yet Assigned | | |
| Sheet | 1 | of | 15 | Attorney Docket Number | SYR-HDAC-5003-U |

| U.S. PATENT DOCUMENTS | | | | | |
|------------------------|--------------------------|--|---|--|---|
| Examiner Initials * | Cite No. ¹ | Document Number | Publication Date/ Issue Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number - Kind Code ² (if known) | | | |
| | AA | 2001/0009922 | 2001-07-26 | Douglas V. Faller | |
| | AB | 2001/0034367 | 2001-10-25 | Douglas V. Faller et al. | |
| | AC | 2002/0065282 | 2002-05-30 | Guy Georges et al. | |
| | AD | 2002/0076457 | 2002-06-20 | Aylward James Harrison | |
| | AE | 2002/0103192 | 2002-08-01 | Michael L. Curtin et al. | |
| | AF | 2002/0107404 | 2002-08-08 | Olaf Prien et al. | |
| | AG | 2002/0115826 | 2002-08-22 | Daniel Delorme et al. | |
| | AH | 2002/0119996 | 2002-08-29 | Hsuan-Yin Lan-Hargest et al. | |
| | AI | 2002/0120099 | 2002-08-29 | Nonkazu Nishino et al. | |
| | AJ | 2002/0132792 | 2002-09-19 | Olaf Prien et al. | |
| | AK | 2002/0137775 | 2002-09-26 | Hsuan-Yin Lan-Hargest et al. | |
| | AL | 2002/0143037 | 2002-10-03 | Hsuan-Yin Lan-Hargest et al. | |
| | AM | 2002/0143052 | 2002-10-03 | Hsuan-Yin Lan-Hargest et al. | |
| | AN | 2002/0143055 | 2002-10-03 | Hsuan-Yin Lan-Hargest et al. | |
| | AO | 2002/0143196 | 2002-10-03 | Hsuan-Yin Lan-Hargest et al. | |
| | AP | 2002/0161045 | 2002-10-31 | Hsuan-Yin Lan-Hargest et al. | |
| | AQ | 2002/0177594 | 2002-11-28 | Michael L. Curtin et al. | |
| | AR | 2002/0183513 | 2002-12-05 | Adelbert Grossmann et al. | |
| | AS | 2003/0013176 | 2003-01-16 | Nikola Pavletich et al. | |
| | AT | 2003/0013757 | 2003-01-16 | Ulrike Leser-Reiff et al. | |
| | AU | 2003/0017454 | 2003-01-23 | Saraswati Sukumar et al. | |
| | AV | 2003/0018062 | 2003-01-23 | Stacy W. Remiszewski et al. | |
| | AW | 2003/0049649 | 2003-03-13 | Alan P. Wolffe et al. | |
| | AX | 2003/0059812 | 2003-03-27 | Victoria M. Richon et al. | |
| | AY | 2003/0078216 | 2003-04-24 | A. Robert MacLeod et al. | |
| | AZ | 2003/0078369 | 2003-04-24 | Peter T. Meinke et al. | |
| | BA | 2003/0082668 | 2003-05-01 | Katsuyuki Tamai et al. | |
| | BB | 2003/0083521 | 2003-05-01 | Hsuan-Yin Lan-Hargest et al. | |
| | BC | 2003/0125306 | 2003-07-03 | Hsuan-Yin Lan-Hargest et al. | |
| | BD | 2003/0129724 | 2003-07-10 | Christina M. Groziner et al. | |
| | BE | 2003/0134865 | 2003-07-17 | Ian Adcock et al. | |
| | BF | 2003/0139404 | 2003-07-24 | Rainer Haag et al. | |
| | BG | 2003/0143712 | 2003-07-31 | Eric Verdin et al. | |
| | BH | 2003/0144276 | 2003-07-31 | Kouichi Kikuchi et al. | |

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|--------------------------|------------------------|-----------------|
| Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i> | | | Complete if Known | | |
| | | | Application Number | 10/682,496 | |
| | | | Filing Date | October 9, 2003 | |
| | | | First Named Inventor | Andrew B. Freistein | |
| | | | Group Art Unit | 1626 | |
| | | | Examiner Name | Not Yet Assigned | |
| Sheet | 2 | of | 15 | Attorney Docket Number | SYR-HDAC-5003-U |

| | | | | | |
|--|----|--------------|------------|-------------------------------|--|
| | BI | 2003/0144340 | 2003-07-31 | Carlin Long et al. | |
| | BJ | 2003/0148970 | 2003-08-07 | Jeffrey M. Besterman et al. | |
| | BK | 2003/0152557 | 2003-08-14 | Jeffrey M. Besterman et al. | |
| | BL | 2003/0171409 | 2003-09-11 | Hsuan-Yin Lan-Hargest et al. | |
| | BM | 2003/0187027 | 2003-10-02 | Stuart L. Schreiber et al. | |
| | BN | 2003/0212121 | 2003-11-13 | Martin Kruger et al. | |
| | BO | 2003/0216345 | 2003-11-20 | Osamu Nakanishi et al. | |
| | BP | 2003/0219832 | 2003-11-27 | Elliott S. Klein et al. | |
| | BQ | 2004/0002506 | 2004-01-01 | Ronald Breslow et al. | |
| | BR | 2004/0014647 | 2004-01-22 | Hyang G. Woo Lee et al. | |
| | BS | 2004/0018968 | 2004-01-29 | George Sgouros | |
| | BT | 2004/0023944 | 2004-02-05 | Hsuan-Yin Lan-Hargest et al. | |
| | BU | 2004/0024067 | 2004-02-05 | Stacy W. Remiszewski et al. | |
| | BV | 2004/0029903 | 2004-02-12 | Hsuan-Yin Lan-Hargest et al. | |
| | BW | 2004/0029922 | 2004-02-12 | Hsuan-Yin Lan-Hargest et al. | |
| | BX | 2004/0053820 | 2004-03-18 | Hidekazu Nakajima et al. | |
| | BY | 2004/0053960 | 2004-03-18 | Guy Georges et al. | |
| | BZ | 2004/0072735 | 2004-04-15 | Victoria M. Richon et al. | |
| | CA | 2004/0072770 | 2004-04-15 | Jeffrey M. Besterman et al. | |
| | CB | 2004/0072849 | 2004-04-15 | Stuart L. Schreiber et al. | |
| | CC | 2004/0077591 | 2004-04-22 | Fernando Dangond | |
| | CD | 2004/0077698 | 2004-04-22 | Guy Georges et al. | |
| | CE | 2004/0077726 | 2004-04-22 | Clare Watkins et al. | |
| | CF | 2004/0087631 | 2004-05-06 | Nicholas G. Bacopoulos et al. | |
| | CG | 2004/0087652 | 2004-05-06 | Martin Gottlicher | |
| | CH | 2004/0087657 | 2004-05-06 | Victoria M. Richon et al. | |
| | CI | 2004/0092431 | 2004-05-13 | Peggy E. Hellberg | |
| | CJ | 2004/0092558 | 2004-05-13 | Peter G. Klinko | |
| | CK | 2004/0092572 | 2004-05-13 | Johanne Renaud et al. | |
| | CL | 2004/0092598 | 2004-05-13 | Clare Watkins et al. | |
| | CM | 2004/0102458 | 2004-05-27 | Gabriela Chiosis et al. | |
| | CN | 2004/0106599 | 2004-06-03 | Daniel Delorme et al. | |
| | CO | 2004/0122079 | 2004-06-24 | Adelbert Grossmann et al. | |
| | CP | 2004/0122101 | 2004-06-24 | Thomas Miller et al. | |
| | CQ | 2004/0138270 | 2004-07-15 | Georg Fertig et al. | |
| | CR | 2004/0157841 | 2004-08-12 | Georg Fertig et al. | |
| | CS | 2004/0157924 | 2004-08-12 | Hsuan-Yin Lan-Hargest et al. | |
| | CT | 2004/0162317 | 2004-08-19 | Georg Fertig et al. | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|----|--------------------------|---------------------|
| Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 10/682,496 |
| | | | | Filing Date | October 9, 2003 |
| | | | | First Named Inventor | Andrew B. Freistein |
| | | | | Group Art Unit | 1626 |
| | | | | Examiner Name | Not Yet Assigned |
| Sheet | 3 | of | 15 | Attorney Docket Number | SYR-HDAC-5003-U |

| | | | | | |
|--|----|--------------|------------|---------------------------------------|--|
| | CU | 2004/0192744 | 2004-09-30 | Rainer Haag et al. | |
| | CV | 2004/0198830 | 2004-10-07 | Clare J. Watkins et al. | |
| | CW | 2004/0214862 | 2004-10-28 | Ulrike Leser-Reiff et al. | |
| | CX | 2004/0214880 | 2004-10-28 | Georg Fertig et al. | |
| | CY | 2004/0224991 | 2004-11-11 | Xian-Ping Lu et al. | |
| | CZ | 2004/0229889 | 2004-11-18 | Yasuharu Urano et al. | |
| | DA | 2004/0254220 | 2004-12-16 | Jerome C. Bressi et al. | |
| | DB | 2004/0266769 | 2004-12-30 | Jerome C. Bressi et al. | |
| | DC | 2004/0266818 | 2004-12-30 | Ronald Breslow et al. | |
| | DD | 2005/0014839 | 2005-01-20 | Alan Kozikowski et al. | |
| | DE | 2005/0026907 | 2005-02-03 | Paul Wash et al. | |
| | DF | 2005/0032794 | 2005-02-10 | Jana K. Padia et al. | |
| | DG | 2005/0032831 | 2005-02-10 | Alan Kozikowski et al. | |
| | DH | 2005/0079995 | 2005-04-14 | Antonio Bedaloy et al. | |
| | DI | 2005/0085507 | 2005-04-21 | Stacy W. Remiszewski et al. | |
| | DJ | 2005/0085515 | 2005-04-21 | Clare J. Watkins et al. | |
| | DK | 2005/0096468 | 2005-05-05 | Kristof Van Emelen et al. | |
| | DL | 2005/0107348 | 2005-05-19 | Hsuan-Yin Lan-Hargest et al. | |
| | DM | 2005/0107384 | 2005-05-19 | Patrick Angibaud et al. | |
| | DN | 2005/0107445 | 2005-05-19 | Clare J. Watkins et al. | |
| | DO | 2005/0113373 | 2005-05-26 | Kristof Van Emelen et al. | |
| | DP | 2005/0119250 | 2005-06-02 | Patrick Angibaud et al. | |
| | DQ | 2005/0124679 | 2005-06-09 | Dae-Kee Kim et al. | |
| | DR | 2005/0131018 | 2005-06-16 | Martin Sendzik et al. | |
| | DS | 2005/0137232 | 2005-06-23 | Jerome C. Bressi et al. | |
| | DT | 2005/0137234 | 2005-06-23 | Jerome C. Bressi et al. | |
| | DU | 2005/0143385 | 2005-06-30 | Clare J. Watkins et al. | |
| | DV | 2005/0148613 | 2005-07-07 | Kristof Van Emelen | |
| | DW | 2005/0159470 | 2005-07-21 | Jerome C. Bressi et al. | |
| | DX | 2005/0165016 | 2005-07-28 | Kristof Van Emelen | |
| | DY | 2005/0171103 | 2005-08-04 | Elaine Sophie Elizabeth Stokes et al. | |
| | DZ | 2005/0171208 | 2005-08-04 | Hsuan-Yin Lan-Hargest et al. | |
| | EA | 2005/0171347 | 2005-08-04 | Kristof Van Emelen | |
| | EB | 2005/0176686 | 2005-08-11 | Alexander B. Maurer et al. | |
| | EC | 4,482,571 | 1984-11-13 | Donald J. Abraham | |
| | ED | 5,124,342 | 1992-06-23 | Francis A.J. Kerdesky et al. | |
| | EE | 5,216,004 | 1993-06-01 | Susan P. Perrine | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|--------------------------|------------------------|-----------------|
| Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i> | | | Complete if Known | | |
| | | | Application Number | 10/682,496 | |
| | | | Filing Date | October 9, 2003 | |
| | | | First Named Inventor | Andrew B. Freistein | |
| | | | Group Art Unit | 1626 | |
| | | | Examiner Name | Not Yet Assigned | |
| Sheet | 4 | of | 15 | Attorney Docket Number | SYR-HDAC-5003-U |

| | | | |
|----|-----------|------------|------------------------------|
| EF | 5,439,939 | 1995-08-08 | Susan P. Perrine |
| EG | 5,645,852 | 1997-07-08 | Harold L. Newmark |
| EH | 5,656,644 | 1997-08-12 | Jerry L. Adams et al. |
| EI | 5,700,826 | 1997-12-23 | Adnan Mjalli et al. |
| EJ | 5,858,365 | 1999-01-12 | Douglas V. Faller |
| EK | 5,922,837 | 1999-07-13 | Peter T. Meinke et al. |
| EL | 5,939,455 | 1999-08-17 | Ada Rephaeli |
| EM | 5,939,456 | 1999-08-17 | Susan P. Perrine |
| EN | 6,011,000 | 2000-01-04 | Susan P. Perrine |
| EO | 6,030,961 | 2000-02-29 | Abraham Nudelman et al. |
| EP | 6,040,342 | 2000-03-21 | Ada Rephaeli et al. |
| EQ | 6,043,277 | 2000-03-28 | Ada Repaeli et al. |
| ER | 6,043,389 | 2000-03-28 | Abraham Nudelman et al. |
| ES | 6,068,987 | 2000-05-30 | Paula M. Dulski et al. |
| ET | 6,110,697 | 2000-08-29 | Paula M. Dulski et al. |
| EU | 6,110,955 | 2000-08-29 | Abraham Nudelman et al. |
| EV | 6,110,970 | 2000-08-29 | Abraham Nudelman et al. |
| EW | 6,124,495 | 2000-09-26 | Edward Neiss et al. |
| EX | 6,130,248 | 2000-10-10 | Abraham Nudelman et al. |
| EY | 6,174,905 | 2001-01-16 | Tsuneji Suzuki et al. |
| EZ | 6,197,743 | 2001-03-06 | Douglas V. Faller |
| FA | 6,231,880 | 2001-05-15 | Susan P. Perrine |
| FB | 6,239,176 | 2001-05-29 | Abraham Nudelman et al. |
| FC | 6,262,116 | 2001-07-17 | Pier Paolo Pandolfi et al. |
| FD | 6,329,402 | 2001-12-11 | Kouichi Kikuchi et al. |
| FE | 6,387,673 | 2002-05-14 | Ronald M. Evans et al. |
| FF | 6,399,568 | 2002-06-04 | Norikazu Nishino et al. |
| FG | 6,403,555 | 2002-06-11 | Soren Skov |
| FH | 6,495,719 | 2002-12-17 | Hsuan-Yin Lan-Hargest et al. |
| FI | 6,511,990 | 2003-01-28 | Ronald Breslow et al. |
| FJ | 6,512,123 | 2003-01-28 | Adelbert Grossmann et al. |
| FK | 6,531,472 | 2003-03-11 | Guy Georges et al. |
| FL | 6,538,030 | 2003-03-25 | Yih-Lin Chang et al. |
| FM | 6,541,661 | 2003-04-01 | Daniel Delorme et al. |
| FN | 6,544,957 | 2003-04-08 | Scott E. Kern et al. |
| FO | 6,548,479 | 2003-04-15 | Soren Skov |
| FP | 6,552,065 | 2003-04-22 | Stacy W. Remiszewski et al. |
| FQ | 6,562,995 | 2003-05-13 | Hsuan-Yin Lan-Hargest et al. |

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|--------------------------|------------------------|-----------------|
| Substitute for form 1449A/PTO | | | Complete if Known | | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | Application Number | 10/682,496 | |
| | | | Filing Date | October 9, 2003 | |
| | | | First Named Inventor | Andrew B. Freistein | |
| | | | Group Art Unit | 1626 | |
| | | | Examiner Name | Not Yet Assigned | |
| Sheet | 5 | of | 15 | Attorney Docket Number | SYR-HDAC-5003-U |

| | | | | | |
|--|----|-----------|------------|------------------------------|--|
| | FR | 6,599,937 | 2003-07-29 | Edward Neiss et al. | |
| | FS | 6,638,530 | 2003-10-28 | Masahiko Ishibashi et al. | |
| | FT | 6,656,905 | 2003-12-02 | Hiroaki Mori et al. | |
| | FU | 6,667,341 | 2003-12-23 | Hsuan-Yin Lan-Hargest et al. | |
| | FV | 6,693,132 | 2004-02-17 | Hsuan-Yin Lan-Hargest et al. | |
| | FW | 6,699,902 | 2004-03-02 | Hsuan-Yin Lan-Hargest et al. | |
| | FX | 6,706,686 | 2004-03-16 | Carlin Long et al. | |
| | FY | 6,720,445 | 2004-04-13 | Hsuan-Yin Lan-Hargest et al. | |
| | FZ | 6,784,173 | 2004-08-31 | Ulrike Leser-Reiff et al. | |
| | GA | 6,800,638 | 2004-10-05 | Guy Georges et al. | |
| | GB | 6,825,317 | 2004-11-30 | Norikazu Nishino et al. | |
| | GC | 6,828,302 | 2004-12-07 | Soren Skov | |
| | GD | 6,831,061 | 2004-12-14 | Hyang Woo Lee et al. | |
| | GE | 6,833,384 | 2004-12-21 | Stacy W. Remiszewski et al. | |
| | GF | 6,841,565 | 2005-01-11 | David M. Lucas et al. | |
| | GG | 6,869,953 | 2005-03-22 | Rainer Haag et al. | |
| | GH | 6,888,027 | 2005-05-03 | Ulrike Leser-Reiff et al. | |
| | GI | 6,897,220 | 2005-05-24 | Daniel Delorme et al. | |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|-----------------------|--|--------------------------------|---|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
| | | | | | | |
| | GJ | WO/0008048 | 2000-02-17 | FUJISAWA PHARMACEUTICAL CO., LTD. | | |
| | GK | WO/00021979 | 2000-04-20 | FUJISAWA PHARMACEUTICAL CO., LTD. | | |
| | GL | WO/00052033 | 2000-09-08 | JAPAN ENERGY CORPORATION | | |
| | GM | WO/00071703 | 2000-11-30 | METHYLGENE INC. | | |
| | GN | WO/00107042 | 2001-02-01 | MERCK & CO., INC. | | |
| | GO | WO/00118171 | 2001-03-15 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | | |
| | GP | WO/00127314 | 2001-04-19 | MERCK & CO., INC. | | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|--------------------------|---------------------|------------------------|-----------------|
| Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i> | | Complete if Known | | | |
| | | Application Number | 10/682,496 | | |
| | | Filing Date | October 9, 2003 | | |
| | | First Named Inventor | Andrew B. Freistein | | |
| | | Group Art Unit | 1626 | | |
| | | Examiner Name | Not Yet Assigned | | |
| Sheet | 6 | of | 15 | Attorney Docket Number | SYR-HDAC-5003-U |

| | | | | | | |
|--|----|-------------|------------|---|--|--|
| | GQ | WO/00138322 | 2001-05-31 | METHYLGENE, INC. | | |
| | GR | WO/00207722 | 2002-01-31 | GEORG-SPEYER-HAUS | | |
| | GS | WO/00215921 | 2002-02-28 | THE GOVERNEMENT OF THE UNITED STATES OF AMERICA, | | |
| | GT | WO/00222133 | 2002-03-21 | VIRGINIA COMMONWEALTH UNIVERSITY | | |
| | GU | WO/00226696 | 2002-04-04 | PROLIFIX LIMITED | | |
| | GV | WO/00226703 | 2002-04-04 | PROLIFIX LIMITED | | |
| | GW | WO/00230879 | 2002-04-18 | PROLIFIX LIMITED | | |
| | GX | WO/0061576 | 2000-10-19 | SMITHKLINE BEECHAM CORPORATION | | |
| | GY | WO/0107042 | 2001-02-01 | MERCK & CO., INC. | | |
| | GZ | WO/0116106 | 2001-03-08 | SCHERING AKTIENGESELLSCHAFT | | |
| | HA | WO/0118045 | 2001-03-15 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | | |
| | HB | WO/0118171 | 2001-03-15 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | | |
| | HC | WO/0127314 | 2001-04-19 | MERCK & CO., INC. | | |
| | HD | WO/0138322 | 2001-05-31 | METHYLGENE, INC. | | |
| | HE | WO/0142437 | 2001-06-14 | AXYS PHARMACEUTICALS, INC. | | |
| | HF | WO/0170675 | 2001-09-27 | METHYLGENE, INC. | | |
| | HG | WO/0172737 | 2001-10-04 | SMITHKLINE BEECHAM CORPORATION | | |
| | HH | WO/02051842 | 2002-07-04 | F. HOFFMANN-LA ROCHE AG | | |
| | HI | WO/02055017 | 2002-07-18 | WAKE FOREST UNIVERSITY | | |
| | HJ | WO/02055688 | 2002-07-18 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, | | |
| | HK | WO/02062773 | 2002-08-15 | F. HOFFMANN-LA ROCHE AG | | |
| | HL | WO/0206307 | 2002-01-24 | FUJISAWA PHARMACEUTICAL CO., LTD. | | |
| | HM | WO/02069947 | 2002-09-12 | METHYLGENE, INC. | | |
| | HN | WO/02076941 | 2002-10-03 | CIRCAGEN PHARMACEUTICAL | | |
| | HO | WO/0207722 | 2002-01-31 | GEORG-SPEYER-HAUS | | |
| | HP | WO/02083173 | 2002-10-24 | DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTS | | |
| | HQ | WO/02085400 | 2002-10-31 | SUPERGEN, INC. | | |
| | HR | WO/02085883 | 2002-10-31 | F. HOFFMANN-LA ROCHE AG | | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|--------------------------|---------------------|------------------------|-----------------|
| Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i> | | Complete if Known | | | |
| | | Application Number | 10/682,496 | | |
| | | Filing Date | October 9, 2003 | | |
| | | First Named Inventor | Andrew B. Freistein | | |
| | | Group Art Unit | 1626 | | |
| | | Examiner Name | Not Yet Assigned | | |
| Sheet | 7 | of | 15 | Attorney Docket Number | SYR-HDAC-5003-U |

| | | | | | | |
|--|----|-------------|------------|--|--|--|
| | HS | WO/02089782 | 2002-11-14 | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | | |
| | HT | WO/02102316 | 2002-12-27 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | | |
| | HU | WO/02102323 | 2001-01-11 | STUDIENGESELLSCHAFT KOHLE MBH | | |
| | HV | WO/0222577 | 2002-03-21 | NOVARTIS AG | | |
| | HW | WO/0226696 | 2002-04-04 | PROLIFIX LIMITED | | |
| | HX | WO/0226703 | 2002-04-04 | PROLIFIX LIMITED | | |
| | HY | WO/0230879 | 2002-04-18 | PROLIFIX LIMITED | | |
| | HZ | WO/0236075 | 2002-05-10 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | | |
| | IA | WO/0246129 | 2002-06-13 | ABBOTT LABORATORIES | | |
| | IB | WO/0246144 | 2002-06-13 | F. HOFFMANN-LA ROCHE AG | | |
| | IC | WO/0246171 | 2002-06-13 | SIGNAL PHARMACEUTICALS, INC. | | |
| | ID | WO/0250244 | 2002-06-27 | ISIS PHARMACEUTICALS, INC. | | |
| | IE | WO/0250285 | 2002-06-27 | NOVARTIS AG | | |
| | IF | WO/03006652 | 2003-01-23 | METHYLGENE, INC. | | |
| | IG | WO/03011851 | 2003-02-13 | F. HOFFMAN-LA ROCHE AG | | |
| | IH | WO/03013493 | 2003-02-20 | ITALFARMACO S.P.A. | | |
| | II | WO/03014340 | 2003-02-20 | NOVARTIS AG | | |
| | IJ | WO/03024442 | 2003-03-27 | G2M CANCER DRUGS AG | | |
| | IK | WO/03024448 | 2003-03-27 | METHYLGENE, INC. | | |
| | IL | WO/03032921 | 2003-04-24 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | | |
| | IM | WO/03039599 | 2003-05-15 | NOVARTIS AG | | |
| | IN | WO/03053468 | 2003-07-03 | UNIVERSITE LIBRE DE BRUXELLES | | |
| | IO | WO/03057722 | 2003-07-17 | FUJISAWA PHARMACEUTICAL CO., LTD. | | |
| | IP | WO/03059864 | 2003-07-24 | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. | | |
| | IQ | WO/03066579 | 2003-08-14 | AXYS PHARMACEUTICALS | | |
| | IR | WO/03066885 | 2003-08-14 | NOVARTIS AG | | |
| | IS | WO/03070188 | 2003-08-28 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | | |
| | IT | WO/03070691 | 2003-08-28 | OSAKA INDUSTRIAL PROMOTION ORGANIZATION | | |
| | IU | WO/03070754 | 2003-08-28 | Minoru YOSHIDA et al. | | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|--------------------------|---------------------|------------------------|-----------------|
| Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i> | | Complete if Known | | | |
| | | Application Number | 10/682,496 | | |
| | | Filing Date | October 9, 2003 | | |
| | | First Named Inventor | Andrew B. Freistein | | |
| | | Group Art Unit | 1626 | | |
| | | Examiner Name | Not Yet Assigned | | |
| Sheet | 8 | of | 15 | Attorney Docket Number | SYR-HDAC-5003-U |

| | | | | | | |
|--|----|-------------|------------|--|--|--|
| | IV | WO/03075839 | 2003-09-18 | ATON PHARMA, INC. | | |
| | IW | WO/03075929 | 2003-09-18 | JANSSEN PHARMACEUTICA N.V. | | |
| | IX | WO/03076395 | 2003-09-18 | JANSSEN PHARMACEUTICA N.V. | | |
| | IY | WO/03076400 | 2003-09-18 | JANSSEN PHARMACEUTICA N.V. | | |
| | IZ | WO/03076401 | 2003-09-18 | JANSSEN PHARMACEUTICA N.V. | | |
| | JA | WO/03076421 | 2003-09-18 | JANSSEN PHARMACEUTICA N.V. | | |
| | JB | WO/03076422 | 2003-09-18 | JANSSEN PHARMACEUTICA N.V. | | |
| | JC | WO/03076430 | 2003-09-18 | JANSSEN PHARMACEUTICA N.V. | | |
| | JD | WO/03076438 | 2003-09-18 | JANSSEN PHARMACEUTICA N.V. | | |
| | JE | WO/03082288 | 2003-10-09 | PROLIFIX LIMITED | | |
| | JF | WO/03083067 | 2003-10-09 | BRIGHAM AND WOMEN'S HOSPITAL, INC. | | |
| | JG | WO/03084611 | 2003-10-16 | FUJISAWA PHARMACEUTICAL CO., LTD. | | |
| | JH | WO/03086397 | 2003-10-23 | KOWA CO., LTD. | | |
| | JI | WO/03087057 | 2003-10-23 | ASTRAZENECA AB | | |
| | JJ | WO/03087066 | 2003-10-23 | SK CHEMICALS, CO., LTD. | | |
| | JK | WO/03088954 | 2003-10-30 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | | |
| | JL | WO/03092686 | 2003-11-13 | ASTRAZENECA AB | | |
| | JM | WO/03099272 | 2003-12-04 | BEACON LABORATORIES, INC. | | |
| | JN | WO/03099760 | 2003-12-04 | BEACON LABORATORIES, INC. | | |
| | JO | WO/03099789 | 2003-12-04 | BEACON LABORATORIES, INC. | | |
| | JP | WO/04002944 | 2004-01-08 | PHARMACIA & UPJOHN COMPANY | | |
| | JQ | WO/04017996 | 2004-03-04 | YAMANOUCHI PHARMACEUTICAL CO. | | |
| | JR | WO/04024160 | 2004-03-25 | VIRGINIA COMMONWEALTH UNIVERSITY | | |
| | JS | WO/04026234 | 2004-04-01 | UNIVERSITY OF SOUTH FLORIDA | | |
| | JT | WO/04052838 | 2004-06-24 | F. HOFFMANN-LA ROCHE AG | | |
| | JU | WO/04053140 | 2004-06-24 | JAWAHARLAL NEHRU CENTRE FOR ADVANCED SCIENTIFIC RESEARCH | | |

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|----|--------------------------|---------------------|
| Substitute for form 1449A/PTO | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Application Number | 10/682,496 |
| | | | | Filing Date | October 9, 2003 |
| | | | | First Named Inventor | Andrew B. Freistein |
| | | | | Group Art Unit | 1626 |
| | | | | Examiner Name | Not Yet Assigned |
| Sheet | 9 | of | 15 | Attorney Docket Number | SYR-HDAC-5003-U |

| | | | | | | |
|--|----|-------------|------------|--|--|--|
| | JV | WO/04054999 | 2004-07-01 | F. HOFFMANN-LA ROCHE AG | | |
| | JW | WO/04063146 | 2004-07-29 | ITALFARMACO SPA | | |
| | JX | WO/04063169 | 2004-07-29 | FUJISAWA PHARMACEUTICAL CO., LTD. | | |
| | JY | WO/04065354 | 2004-08-05 | TOPOTARGET UK LIMITED | | |
| | JZ | WO/04067480 | 2004-08-12 | OXFORD GLYCOSCIENCES (UK) LTD | | |
| | KA | WO/04069823 | 2004-08-19 | METHYLGENE, INC. | | |
| | KB | WO/04076386 | 2004-09-10 | TOPOTARGET UK LIMITED | | |
| | KC | WO/04082638 | 2004-09-30 | SYRRX, INC. | | |
| | KD | WO/04092115 | 2004-10-28 | AXYS PHARMACEUTICALS INC. | | |
| | KE | WO/04110418 | 2004-12-23 | KALYPSYS, INC. | | |
| | KF | WO/04113336 | 2004-12-29 | CHROMA THERAPEUTICS LIMITED | | |
| | KG | WO/04113366 | 2004-12-29 | RIKEN | | |
| | KH | WO/05004861 | 2005-01-20 | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY | | |
| | KI | WO/05011661 | 2005-02-10 | UNIVERSITY COLLEGE LONDON | | |
| | KJ | WO/05014588 | 2005-02-17 | ARGENTA DISCOVERY LIMITED | | |
| | KK | WO/05016264 | 2005-02-24 | AVALON PHARMACEUTICALS | | |
| | KL | WO/05018578 | 2005-03-03 | ATON PHARMA, INC. | | |
| | KM | WO/05019174 | 2005-03-03 | AXYS PHARMACEUTICALS, INC. | | |
| | KN | WO/05028447 | 2005-03-31 | S'BIO PTE LTD | | |
| | KO | WO/05030704 | 2005-04-07 | METHYLGENE, INC. | | |
| | KP | WO/05030705 | 2005-04-07 | METHYLGENE, INC. | | |
| | KQ | WO/05034880 | 2005-04-21 | ATON PHARMA, INC. | | |
| | KR | WO/05039498 | 2005-05-06 | ATON PHARMA, INC. | | |
| | KS | WO/05040101 | 2005-05-06 | S'BIO PTE LTD | | |
| | KT | WO/05040161 | 2005-05-06 | S'BIO PTE LTD | | |
| | KU | WO/05047457 | 2005-05-26 | JAWAHARLAL NEHRU CENTRE FOR ADVANCED SCIENTIFIC RESEARCH | | |
| | KV | WO/05051901 | 2005-06-09 | THE UNIVERSITY OF QUEENSLAND | | |
| | KW | WO/05053610 | 2005-06-16 | ATON PHARMA, INC. | | |

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|----|----|----|--------------------------|---------------------|
| Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 10/682,496 |
| | | | | Filing Date | October 9, 2003 |
| | | | | First Named Inventor | Andrew B. Freistein |
| | | | | Group Art Unit | 1626 |
| | | | | Examiner Name | Not Yet Assigned |
| Sheet | 10 | of | 15 | Attorney Docket Number | SYR-HDAC-5003-U |

| | | | | | | |
|--|----|----------------|------------|---|--|--|
| | KX | WO/05055928 | 2005-06-23 | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION | | |
| | KY | WO/05058298 | 2005-06-30 | WISCONSIN ALUMNI RESEARCH FOUNDATION | | |
| | KZ | WO/05058803 | 2005-06-30 | EXONHIT THERAPEUTICS SA | | |
| | LA | WO/05065681 | 2005-07-21 | SYRRX, INC. | | |
| | LB | WO/05066151 | 2005-07-21 | SYRRX, INC. | | |
| | LC | WO/09711366 | 1997-03-27 | MERCK & CO., INC. | | |
| | LD | WO/09735990 | 1997-10-02 | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | | |
| | LE | WO/09747307 | 1997-12-18 | THE UAB RESEARCH FOUNDATION | | |
| | LF | WO/09800127 | 1998-01-08 | Ada REPHAELI | | |
| | LG | WO/9826773 | 1998-06-25 | WARNER-LAMBERT COMPANY | | |
| | LH | WO/98291114 | 1998-07-09 | BEACON LABORATORIES L.L.C. | | |
| | LI | WO/98339966 | 1998-09-17 | BEACON LABORATORIES, L.L.C. | | |
| | LJ | WO/9840065 | 1998-09-17 | BEACON LABORATORIES, L.L.C. | | |
| | LK | WO/9840080 | 1998-09-17 | BEACON LABORATORIES, L.L.C. | | |
| | LL | WO/09911659 | 1999-03-11 | JAPAN ENERGY CORPORATION | | |
| | LM | WO/09923885 | 1999-05-20 | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES | | |
| | LN | WO/2002076941 | 2002-10-03 | CIRCAGEN PHARMACEUTICAL | | |
| | LO | WO/2003006652 | 2003-01-23 | METHYLGENE, INC. | | |
| | LP | WO/2004/002944 | 2004-01-08 | PHARMACIA & UPJOHN COMPANY | | |
| | LQ | WO/2004005282 | 2004-01-15 | NOVARTIS AG | | |
| | LR | WO/2004005513 | 2004-01-15 | METHYLGENE, INC. | | |
| | LS | WO/2004009536 | 2004-01-29 | 4SC AG | | |
| | LT | WO/2004013130 | 2004-02-12 | ARGENTA DISCOVERY LIMITED | | |
| | LU | WO/2004/017996 | 2004-03-04 | YAMANOUCI PHARMACEUTICAL CO., LTD. | | |
| | LV | WO/2004020460 | 2004-03-11 | YAMANOUCI PHARMACEUTICAL CO., LTD. | | |
| | LW | WO/2004024160 | 2004-03-25 | VIRGINIA COMMONWEALTH UNIVERSITY | | |
| | LX | WO/2004026234 | 2004-04-01 | UNIVERSITY OF SOUTH FLORIDA | | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|----|--------------------------|---------------------|------------------------|-----------------|
| Substitute for form 1449A/PTO | | Complete if Known | | | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | 10/682,496 | | |
| | | Filing Date | October 9, 2003 | | |
| | | First Named Inventor | Andrew B. Freistein | | |
| | | Group Art Unit | 1626 | | |
| | | Examiner Name | Not Yet Assigned | | |
| Sheet | 11 | of | 15 | Attorney Docket Number | SYR-HDAC-5003-U |

| | | | | | |
|----|---------------|------------|---|--|--|
| LY | WO/2004035525 | 2004-04-29 | METHYLGENE INC. | | |
| MA | WO/2004043348 | 2004-05-27 | ALCON, INC. | | |
| MB | WO/2004043352 | 2004-05-27 | ALCON, INC. | | |
| MC | WO/2004046094 | 2004-06-03 | QUEEN MARY & WESTFIELD COLLEGE | | |
| MD | WO/2004046104 | 2004-06-03 | BEACON LABORATORIES | | |
| ME | WO/2004069133 | 2004-08-19 | F. HOFFMANN-LA ROCHE AG | | |
| MF | WO/2004069803 | 2004-08-19 | F. HOFFMANN-LA ROCHE AG | | |
| MG | WO/2004069823 | 2004-08-19 | METHYLGENE, INC. | | |
| MH | WO/2004071400 | 2004-08-26 | SHENZHEN CHIPSCREEN BIOSCIENCES LTD. | | |
| MI | WO/2004071401 | 2004-08-26 | FUJISAWA PHARMACEUTICAL CO., LTD. | | |
| MJ | WO/9307124 | 1993-04-15 | EISAI CO., LTD. | | |
| MK | WO/9615096 | 1996-05-23 | BAYER CORPORATION | | |
| ML | WO/9702244 | 1997-01-23 | Kouichi KIKUCHI | | |
| MM | WO/9828269 | 1998-07-02 | THE DUPONT MERCK PHARMACEUTICAL COMPANY | | |
| MN | WO/9961413 | 1999-12-02 | BAYER CORPORATION | | |
| MO | EP/0847992 | 1998-06-17 | mitsui chemicals, inc. | | |

| OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS | | | |
|--|-----------------------|--|----------------|
| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | MP | BOUCHAIN, GILIANE et al., Development of Potential Antitumor Agents. Synthesis and Biological Evaluation of a New Set of Sulfonamide Derivatives as Histone Deacetylase Inhibitors, Journal of Medicinal Chemistry, (2003) Vol. 46, pp. 820-830, American Chemical Society | |
| | MQ | CAMPHAUSEN, K. et al., Enhanced Radiation-Induced Cell Killing and Prolongation of γ H2AX Foci Expression by the Histone Deacetylase Inhibitor MS-275, Cancer Research, (01/01/2004), Vol. 64, pp. 316-321, Maryland. | |
| | MR | CATLEY, L. et al., NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma, Blood, (10/01/2003), Vol. 102(7), pp. 2615-22, Epub. | |
| | MS | COLLETTI, STEVEN L. et al., Broad Spectrum Antiprotozoal Agents that Inhibit Histone Deacetylase: Structure—Activity Relationships of Apicidin. Part 1 and Part 2, Bioorganic & Medicinal Chemistry Letters, (2001), Vol. 11, pp. 107-111, Elsevier Science Ltd. | |
| | MT | CURTIN, MICHAEL et al., Histone Deacetylase Inhibitors: The Abbott Experience, Current Medicinal Chemistry, (2003), Vol. 10, 1241-1253, Bentham Science Publishers Ltd. | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | | | | | | | | | | | |
|--|---------------------|---|----|--------------------|------------|-------------|-----------------|----------------------|---------------------|----------------|------|---------------|------------------|------------------------|-----------------|
| Substitute for form 1449A/PTO <h2 style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center;">(use as many sheets as necessary)</p> | | <h3 style="text-align: center;">Complete if Known</h3> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">Application Number</td> <td>10/682,496</td> </tr> <tr> <td>Filing Date</td> <td>October 9, 2003</td> </tr> <tr> <td>First Named Inventor</td> <td>Andrew B. Freistein</td> </tr> <tr> <td>Group Art Unit</td> <td>1626</td> </tr> <tr> <td>Examiner Name</td> <td>Not Yet Assigned</td> </tr> <tr> <td>Attorney Docket Number</td> <td>SYR-HDAC-5003-U</td> </tr> </table> | | Application Number | 10/682,496 | Filing Date | October 9, 2003 | First Named Inventor | Andrew B. Freistein | Group Art Unit | 1626 | Examiner Name | Not Yet Assigned | Attorney Docket Number | SYR-HDAC-5003-U |
| Application Number | 10/682,496 | | | | | | | | | | | | | | |
| Filing Date | October 9, 2003 | | | | | | | | | | | | | | |
| First Named Inventor | Andrew B. Freistein | | | | | | | | | | | | | | |
| Group Art Unit | 1626 | | | | | | | | | | | | | | |
| Examiner Name | Not Yet Assigned | | | | | | | | | | | | | | |
| Attorney Docket Number | SYR-HDAC-5003-U | | | | | | | | | | | | | | |
| Sheet | 12 | of | 15 | | | | | | | | | | | | |

| | | | |
|--|----|--|--|
| | MU | DAI, YUJIA et al., Indole Amide Hydroxamic Acids as Potent Inhibitors of Histone Deacetylase, Bioorganic and Medicinal Chemistry Letters, (2003), pp. 1-5, Abbott Park, IL. | |
| | MV | DARKIN-RATTRAY, SANDRA J. et al., Apicidin: A novel antiprotozoal agent that inhibits parasite histone deacetylase, Proceedings of the National Academy of Sciences, (November 1996), Vol. 93, pp.13143-14147, West Point, PA. | |
| | MW | FOURNEL, MARIELLE et al., Sulfonamide Anilides, a Novel Class of Histone Deacetylase Inhibitors, Are Antiproliferative against Human Tumors, Cancer Research, (08/01/2002), Vol. 62, pp. 4325-4330, Quebec, Canada. | |
| | MX | FREY, ROBIN R. et al., Trifluoromethyl Ketones as Inhibitors of Histone Deacetylase, Bioorganic & Medicinal Chemistry Letters, (2002), pp. 3443-3447. | |
| | MY | FURUMAI, RYOHEI et al., Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin, Proceedings of the National Academy of Sciences, (01/02/2001), Vol. 98, No. 1, pp. 87-92, New York, NY. | |
| | MZ | GLASER, KEITH B. et al., Gene Expression Profiling of Multiple Histone Deacetylase (HDAC) Inhibitors: Defining a Common Gene Set Produced by HDAC Inhibition in T24 and MDA Carcinoma Cell Lines, Molecular Cancer Therapeutics, (2003), Vol. 2, pp. 151-163. | |
| | NA | GROZINGER, CHRISTINA et al., Deacetylase Enzymes: Biological Functions and the Use of Small-Molecule Inhibitors, Chemistry & Biology, (2002), Vol. 9, pp. 3 -16, Elsevier Science Ltd. | |
| | NB | HAGGARTY, STEPHEN J. et al., Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation, Proceedings of the National Academy of Sciences, (04/15/2003) Vol. 100, No. 8, pp. 4389-4394. | |
| | NC | HU, ERDING et al., Identification of Novel Isoform-Selective Inhibitors within Class I Histone Deacetylases, The Journal of Pharmacology and Experimental Therapeutics, (2003), Vol. 307, No. 2, pp. 720-728, The American Society for Pharmacology and Experimental Therapeutics. | |
| | ND | JABOIN, JERRY et al., MS-27-275, an Inhibitor of Histone Deacetylase, Has Marked in Vitro and in Vivo Antitumor Activity against Pediatric Solid Tumors, Cancer Research, (11/01/2002), Vol. 62, pp. 6108-6115. | |
| | NE | JOSE, BINOY et al., Toward an HDAC6 Inhibitor: synthesis and conformational analysis of cyclic hexapeptide hydroxamic acid designed from α -tubulin sequence Toward an HDAC6 Inhibitor: synthesis and conformational analysis of cyclic hexapeptide hydroxamic acid designed from α -tubulin sequence, Bioorganic & Medicinal Chemistry, (2004), Vol. 12, pp. 1351-1356, Elsevier Ltd. | |
| | NF | JUNG, MANFRED et al., Amide Analogues of Trichostatin A as Inhibitors of Histone Deacetylase and Inducers of Terminal Cell Differentiation, Journal of Medicinal Chemistry, (1999), Vol. 42, 4669-4679, American Chemical Society. | |
| | NG | KAPUSTIN, GALINA V. et al., Phosphorus-Based SAHA Analogues as Histone Deacetylase Inhibitors, Organic Letters, (2003), Vol. 0, No. 0, pp. A-D, American Chemical Society. | |
| | NH | KOMATSU, YASUHIKO et al., Cyclic Hydroxamic-acid-containing Peptide 31, a Potent Synthetic Histone Deacetylase Inhibitor with Antitumor Activity, Cancer Research, (06/01/2001), Vol. 61, pp. 4459-4466. | |
| | NI | KRAKER, ALAN J. et al., Modulation of Histone Acetylation by [4-(Acetylamino)-N-(2-Amino-phenyl) Benzamide] in HCT-8 Colon Carcinoma, Molecular Cancer Therapeutics, (2003), Vol. 2, pp. 401-408. | |
| | NJ | LAVOIE, RICO et al., Design and Synthesis of a Novel Class of Histone Deacetylase Inhibitors, Bioorganic & Medicinal Chemistry Letters, (2001), Vol. 11, pp. 2847-2850, Elsevier Science Ltd. | |

| | | |
|--------------------|-----------------|--|
| Examiner Signature | Date Considered | |
|--------------------|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|----|--------------------------|---------------------|------------------------|-----------------|
| Substitute for form 1449A/PTO | | Complete if Known | | | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | 10/682,496 | | |
| | | Filing Date | October 9, 2003 | | |
| | | First Named Inventor | Andrew B. Freistein | | |
| | | Group Art Unit | 1626 | | |
| | | Examiner Name | Not Yet Assigned | | |
| Sheet | 13 | of | 15 | Attorney Docket Number | SYR-HDAC-5003-U |

| | |
|----|--|
| NK | LEE, BYOUNG ICK et al., MS-275, A Histone Deacetylase Inhibitor, Selectively Induces Transforming Growth Factor β Type II Receptor Expression in Human Breast Cancer Cells, Cancer Research, (02/01/2001), Vol. 61, pp. 931-934. |
| NL | LU, QIANG et al., Zn^{2+} -Chelating, Motif-Tethered, Short-Chain Fatty Acids as a Novel Class of Histone Deacetylase Inhibitors, Journal of Medicinal Chemistry, (2004), Vol. 47, pp. 467-474, American Chemical Society. |
| NM | MAGGIO, SONIA C., The Histone Deacetylase Inhibitor MS-275 Interacts Synergistically with Fludarabine to Induce Apoptosis in Human Leukemia Cells, Cancer Research, (04/01/2004), Vol. 64, pp. 2590-2600. |
| NN | MAI, ANTONELLO et al., Binding Mode Analysis of 3-(4-Benzoyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamide: a New Synthetic Histone Deacetylase Inhibitor Inducing Histone Hyperacetylation, Growth Inhibition, and Terminal Cell Differentiation, Journal of Medicinal Chemistry, (2002), Vol. 45, pp. 1778-1784, American Chemical Society. |
| NO | MAI, ANTONELLO et al., 3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-alkylamides as a New Class of Synthetic Histone Deacetylase Inhibitors. 1. Design, Synthesis, Biological Evaluation, and Binding Mode Studies Performed through Three Different Docking Procedures, Journal of Medicinal Chemistry, (2003), Vol. 46, pp. 512-524, American Chemical Society. |
| NP | MAI, ANTONELLO et al., 3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-alkylamides as a New Class of Synthetic Histone Deacetylase Inhibitors. 2. Effect of Pyrrole- C_2 and/or - C_4 Substitutions on Biological Activity, Journal of Medicinal Chemistry, (2003), pp. A-L, American Chemical Society. |
| NQ | MAI, ANTONELLO et al., Discovery of (Aryloxopropenyl)pyrrolyl Hydroxyamides as Selective Inhibitors of Class IIa Histone Deacetylase Homologue HD1-A, Journal of Medicinal Chemistry, (2003), pp. A-D, American Chemical Society. |
| NR | MARKS, PAUL A. et al., Histone Deacetylase Inhibitors as New Cancer Drugs, Current Opinion in Oncology, (2001), Vol. 13, pp. 477-483, Lippincott Williams & Wilkins, Inc. |
| NS | MASSA, SILVIO et al., 3-(4-Aroyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides, a New Class of Synthetic Histone Deacetylase Inhibitors, Journal of Medicinal Chemistry, (2001), Vol. 44, pp. 2069-2072, American Chemical Society. |
| NT | MEINKE, PETER et al., Synthesis of Apicidin-Derived Quinolone Derivatives: Parasite-Selective Histone Deacetylase Inhibitors and Antiproliferative Agents, Journal of Medicinal Chemistry, (2000), Vol. 43, pp. 4919-4922, American Chemical Society. |
| NU | MILLER, THOMAS A. et al., Histone Deacetylase Inhibitors, Journal of Medicinal Chemistry, (11/20/2003), Vol. 46, No. 24, pp. 5097-5116, American Chemical Society. |
| NV | NISHINO, NORIKAZU et al., Cyclic Tetrapeptides Bearing a Sulfhydryl Group Potently Inhibit Histone Deacetylase, Organic Letters, (2003), Vol. 0, No. 0, pp. A-D, American Chemical Society. |
| NW | PINA, IVETTE C. et al., Psammaplins from the Sponge Pseudoceratina purpurea: Inhibition of Both Histone Deacetylase and DNA Methyltransferase, Journal of Organic Chemistry, (02/24/2003), pp. A-H, American Chemical Society. |
| NX | PLUMB, JANE et al., Pharmacodynamic Response and Inhibition of Growth of Human Tumor Xenografts by the Novel Histone Deacetylase Inhibitor PXD101, Molecular Cancer Therapeutics, (August 2003), Vol. 2, pp. 721-728. |
| NY | PRAKASH, SUCHARU et al., Chronic oral administration of CI-994: a Phase 1 Study, Investigational New Drugs, (2001), Vol. 19, pp. 1-11, Kluwer Academic Publishers, Netherlands. |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|----|--------------------------|---------------------|------------------------|-----------------|
| Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i> | | Complete if Known | | | |
| | | Application Number | 10/682,496 | | |
| | | Filing Date | October 9, 2003 | | |
| | | First Named Inventor | Andrew B. Freistein | | |
| | | Group Art Unit | 1626 | | |
| | | Examiner Name | Not Yet Assigned | | |
| Sheet | 14 | of | 15 | Attorney Docket Number | SYR-HDAC-5003-U |

| | | |
|----|---|--|
| NZ | RAGNO, RINO et al., 3-(4-Aroyl-1-methyl-1 H-pyrrol-2-yl)-N-hydroxy-2-propenamides as a New Class of Synthetic Histone Deacetylase Inhibitors. 3. Discovery of New Lead Compounds through Structure-Based Drug Design and Docking Studies, Journal of Medicinal Chemistry, (2004), Vol. 47, pp. 1351-1359, American Chemical Society. | |
| OA | REMISZEWSKI, STACY et al., Inhibitors of Human Histone Deacetylase: Synthesis and Enzyme and Cellular Activity of Straight Chain Hydroxamates, Journal of Medicinal Chemistry, (02/14/2002), Vol. 45, No. 4, pp. 753-757, American Chemical Society. | |
| OB | REMISZEWSKI, STACY, Recent Advances in the Discovery of Small Molecule Histone Deacetylase Inhibitors, Current Opinion Drug Discovery Development, (07/05/2002), "abstract." | |
| OC | REMISZEWSKI, STACY et al., N-Hydroxy-3-phenyl-2-propenamides as Novel Inhibitors of Human Histone Deacetylase with in Vivo Antitumor Activity: Discovery of (2E)-N-Hydroxy-3-[4-[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl-phenyl]-2-propenamide (NVP-LAQ824), Journal of Medicinal Chemistry, (05/15/2003), pp. A-P, American Chemical Society. | |
| OD | REMISZEWSKI, STACY, The Discovery of NVP-LAQ824: From Concept to Clinic, Current Medicinal Chemistry, (11/10/2003), "abstract" | |
| OE | ROSATO, ROBERTO R., The Histone Deacetylase Inhibitor MS-275 Promotes Differentiation or Apoptosis in Human Leukemia Cells through a Process Regulated by Generation of Reactive Oxygen Species and Induction of p21 ^{CIP1/WAF1} , Cancer Research, (07/01/2003), Vol. 63, pp. 3637-3645. | |
| OF | SAITO, AKIKO et al. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors, Proceedings of the National Academy of Sciences, (April 1999), Vol. 96, pp. 4592-4597. | |
| OG | SINGH, SHEO et al., Structure, Histone Deacetylase, and Antiprotozoal Activities of Apidicidins B and C, Congeners of Apidicin with Praline and Valine Substitutions., Organic Letters, (09/06/2001), "abstract." | |
| OH | SINGH, SHEO et al., Structure and Chemistry of Apidicidins, a Class of Novel Cyclic Tetrapeptides without a Terminal α -Keto Epoxide as Inhibitors of Histone Deacetylase with Potent Antiprotozoal Activities, Journal of Organic Chemistry, (2002), Vol. 67, pp. 815-825, American Chemical Society. | |
| OI | Sternson, Scott et al., Synthesis of 7200 Small Molecules Based on a Substructural Analysis of the Histone Deacetylase Inhibitors Trichostatin and Trapoxin, Organic Letters, (2001), Vol. 3, pp. 4239-4242, American Chemical Society. | |
| OJ | SU, GLORIA et al., A Novel Histone Deacetylase Inhibitor Identified by High-Throughput Transcriptional Screening of a Compound Library, Cancer Research, (06/15/2000), Vol. 60, pp. 3137-3142. | |
| OK | SUZUKI, TAKAYOSHI et al., Novel Histone Deacetylase Inhibitors: Design, Synthesis, Enzyme Inhibition, and Binding Mode Study of SAHA-Based Non-hydroxamates, Bioorganic & Medicinal Chemistry Letters, (2003), Vol. 13, pp. 4321-4326, Elsevier Ltd. | |
| OL | SUZUKI, TSUNEJI et al., Synthesis and Histone Deacetylase Inhibitory Activity of New Benzamide Derivatives, Journal of Medicinal Chemistry, (1999), Vol. 42, pp. 3001-3003, American Chemical Society. | |
| OM | TAUNTON, JACK et al., Synthesis of Natural and Modified Trapoxins, Useful Reagents for Exploring Histone Deacetylase Function, Journal of American Chemical Society, (1996), Vol. 118, pp. 10412-10422, American Chemical Society. | |
| ON | UESATO, SHINICHI et al., Novel Histone Deacetylase Inhibitors: N-Hydroxycarboxamides Possessing a Terminal Bicyclic Aryl Group, Bioorganic & Medicinal Chemistry Letters, (2002), Vol. 12, pp. 1347-1349, Elsevier Science Ltd. | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|----|--------------------------|---------------------|------------------------|-----------------|
| Substitute for form 1449A/PTO | | Complete if Known | | | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | 10/682,496 | | |
| | | Filing Date | October 9, 2003 | | |
| | | First Named Inventor | Andrew B. Freistein | | |
| | | Group Art Unit | 1626 | | |
| | | Examiner Name | Not Yet Assigned | | |
| Sheet | 15 | of | 15 | Attorney Docket Number | SYR-HDAC-5003-U |

| | | | |
|--|----|---|--|
| | OO | VAISBURG, ARKADII et al., (2-Amino-phenyl)-amides of ω -substituted alkanolic acids as net histone deacetylase inhibitors, Bioorganic & Medicinal Chemistry Letters, (2004), Vol. 14, pp. 283-287, Elsevier Ltd. | |
| | OP | VAN OMMESLAEGHE, K. et al., Amide Analogues of TSA: Synthesis, Binding Mode Analysis and HDAC Inhibition, Bioorganic & Medicinal Chemistry Letters, (2003), Vol. 13, pp. 1861-1864, Elsevier Science Ltd. | |
| | OQ | VASUDEVAN, ANIL et al., Heterocyclic Ketones as Inhibitors of Histone Deacetylase, Bioorganic & Medicinal Chemistry Letters, (2003), pp. 1-5, Elsevier Ltd. | |
| | OR | WANG, DI-FEI et al., QSAR Studies of PC-3 cell line inhibition activity of TSA and SAHA-like hydroxamic acids, Bioorganic & Medicinal Chemistry Letters, (2004), Vol. 14, pp. 707-711, Elsevier-Ltd. | |
| | OS | WITTICH, SYBILLE et al., Structure—Activity Relationships on Phenylalanine-Containing Inhibitors of Histone Deacetylase: In Vitro Enzyme Inhibition, Induction of Differentiation, and Inhibition of Proliferation in Friend Leukemic Cells, Journal of Medicinal Chemistry, (2002), Vol. 45, pp. 3296-3309, American Chemical Society. | |
| | OT | WONG, JASON C. et al., Structural Biasing Elements for In-Cell Histone Deacetylase Paralog Selectivity, Journal of American Chemical Society, (04/16/2003), Vol. 125, pp. 5586-5587, American Chemical Society. | |
| | OU | WOO, SOON HYUNG et al., Structurally Simple Trichostatin A-Like Straight Chain Hydroxamates as Potent Histone Deacetylase Inhibitors, Journal of Medicinal Chemistry, (2002), Vol. 45, pp. 2877-2885, American Chemical Society. | |
| | OV | WU, TOM Y. H. et al., Design, synthesis, and activity of HDAC inhibitors with a N-formyl hydroxylamine head group, Bioorganic & Medicinal Chemistry Letters, (2004), Vol. 14, pp. 449-453, Elsevier Ltd. | |
| | OW | YUREK-GEORGE, ALEXANDER et al., Total Synthesis of Spiruchostatin A, a Potent Histone Deacetylase Inhibitor, Journal of American Chemical Society, (2003), Vol. 126, pp. 1030-1031, American Chemical Society. | |
| | OX | ZHANG, YUBIN et al., Histone Deacetylase Inhibitors FK228, N-(2-ANINOPHENYL)-4-[N-(PYRIDIN-3-YL-METHOXYCARBONYL) AMINO-METHYL]BENZAMIDE AND m-CARBOXYCINNAMIC ACID BIS-HYDROXAMIDE AUGMENT RADIATION-INDUCED CELL DEATH IN GASTROINTESTINAL ADENOCARCINOMA CELLS, Int. Journal of Cancer, (2004) Vol. 110, pp. 301-308, Wiley InterScience. | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.